Global Vaccine for Influenza Supply, Demand and Key Producers, 2026-2032
Description
The global Vaccine for Influenza market size is expected to reach $ 13930 million by 2032, rising at a market growth of 5.4% CAGR during the forecast period (2026-2032).
The Influenza Vaccine is a biological product designed to stimulate the human immune system to produce virus-specific antibodies, thereby preventing seasonal influenza infection and reducing the risks of severe illness, complications, and mortality. Its mechanism relies on inactivated, attenuated, recombinant, or genetically engineered antigen delivery technologies that safely induce protective immune memory. As one of the most strategic public-health tools worldwide, influenza vaccines are incorporated into national immunization programs or prioritized recommendations by health authorities to lower disease burden, reduce healthcare utilization, and protect high-risk populations such as the elderly, patients with chronic conditions, pregnant women, and children. With continuous viral mutation and strengthened global surveillance, influenza vaccines are undergoing ongoing innovation in formulation updates, platform technologies, strain-matching optimization, and production efficiency, thereby supporting population health, medical cost containment, and sustainable industry growth.In 2024, global Vaccine for Influenza production reached approximately 845.8 m units, with an average global market price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%.
The strengthening of global public-health systems is transforming influenza vaccines from “seasonal demand products” into “fundamental health-protection tools.” Governments are increasing investment in preventive medicine, expanding immunization coverage, and enhancing protection for key populations, creating stable demand momentum. Annual reports of major vaccine companies highlight continuous upgrades in mRNA, recombinant protein, and adjuvant-enhanced platforms, improving antigenicity, production speed, and strain-matching accuracy. Regulatory reforms in approval pathways, manufacturing upgrades, and international harmonization are enhancing supply-chain resilience. As enterprises, healthcare institutions, and insurers increasingly recognize the economic impact of influenza peaks, vaccines are positioned as the most cost-effective preventive solution, supporting long-term growth.
The industry faces uncertainties due to continuous viral mutation, requiring ongoing strain adaptation and formulation updates that increase R&D and manufacturing pressure. In some countries, limited public awareness or high out-of-pocket vaccination costs lead to fluctuating uptake rates. The reliance on specific upstream materials and specialized manufacturing equipment means that global logistics, regulatory adjustments, or regional policy changes can impact capacity deployment. Annual reports also indicate intensified competition, with novel technology platforms entering rapidly, forcing traditional manufacturers to invest heavily in R&D and production upgrades. Differing cold-chain standards across countries add further complexity to cross-border distribution.
Demand is shifting from “seasonal vaccination” to “routine immunization management,” particularly among high-risk groups such as the elderly, respiratory-disease patients, and healthcare workers. Hospitals, schools, and large enterprises increasingly adopt centralized procurement to mitigate the operational impact during influenza peaks. With rising consumer awareness, quadrivalent vaccines, high-immunogenicity formulations, preservative-free products, and next-generation platforms are seeing faster penetration. Expanded deployment of community clinics, pharmacies, and mobile vaccination points is improving accessibility. Corporate and insurance-driven population-health programs are also steering demand toward higher-quality vaccines.
Key upstream inputs include seed viruses, cell substrates, specialized culture media, adjuvant systems, and sterile-filling consumables, with global suppliers relatively concentrated. Annual reports show that advanced platforms require higher purity, stability, and consistency in antigen and adjuvant materials, increasing the technological intensity and quality sensitivity of the supply chain. As egg-based, cell-based, and recombinant systems evolve in parallel, differences in raw materials have a direct impact on process efficiency and capacity scalability. Requirements for cold-chain packaging, quality-control reagents, and testing consumables are also rising, pushing the upstream ecosystem toward higher standards and broader internationalization.
This report studies the global Vaccine for Influenza production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Vaccine for Influenza and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Vaccine for Influenza that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Vaccine for Influenza total production and demand, 2021-2032, (M Units)
Global Vaccine for Influenza total production value, 2021-2032, (USD Million)
Global Vaccine for Influenza production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (M Units), (based on production site)
Global Vaccine for Influenza consumption by region & country, CAGR, 2021-2032 & (M Units)
U.S. VS China: Vaccine for Influenza domestic production, consumption, key domestic manufacturers and share
Global Vaccine for Influenza production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (M Units)
Global Vaccine for Influenza production by Type, production, value, CAGR, 2021-2032, (USD Million) & (M Units)
Global Vaccine for Influenza production by Application, production, value, CAGR, 2021-2032, (USD Million) & (M Units)
This report profiles key players in the global Vaccine for Influenza market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Vaccine for Influenza market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (M Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Vaccine for Influenza Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Vaccine for Influenza Market, Segmentation by Type:
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Global Vaccine for Influenza Market, Segmentation by Technology:
Chicken Embryo Technology
Cell Culture Technology
Recombinant Technology
Adjuvant Vaccines
Global Vaccine for Influenza Market, Segmentation by Administration:
Injectable
Nasal Spray
Global Vaccine for Influenza Market, Segmentation by Application:
6 Months to 3 Years
> 3 Years
Companies Profiled:
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Key Questions Answered:
1. How big is the global Vaccine for Influenza market?
2. What is the demand of the global Vaccine for Influenza market?
3. What is the year over year growth of the global Vaccine for Influenza market?
4. What is the production and production value of the global Vaccine for Influenza market?
5. Who are the key producers in the global Vaccine for Influenza market?
6. What are the growth factors driving the market demand?
The Influenza Vaccine is a biological product designed to stimulate the human immune system to produce virus-specific antibodies, thereby preventing seasonal influenza infection and reducing the risks of severe illness, complications, and mortality. Its mechanism relies on inactivated, attenuated, recombinant, or genetically engineered antigen delivery technologies that safely induce protective immune memory. As one of the most strategic public-health tools worldwide, influenza vaccines are incorporated into national immunization programs or prioritized recommendations by health authorities to lower disease burden, reduce healthcare utilization, and protect high-risk populations such as the elderly, patients with chronic conditions, pregnant women, and children. With continuous viral mutation and strengthened global surveillance, influenza vaccines are undergoing ongoing innovation in formulation updates, platform technologies, strain-matching optimization, and production efficiency, thereby supporting population health, medical cost containment, and sustainable industry growth.In 2024, global Vaccine for Influenza production reached approximately 845.8 m units, with an average global market price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%.
The strengthening of global public-health systems is transforming influenza vaccines from “seasonal demand products” into “fundamental health-protection tools.” Governments are increasing investment in preventive medicine, expanding immunization coverage, and enhancing protection for key populations, creating stable demand momentum. Annual reports of major vaccine companies highlight continuous upgrades in mRNA, recombinant protein, and adjuvant-enhanced platforms, improving antigenicity, production speed, and strain-matching accuracy. Regulatory reforms in approval pathways, manufacturing upgrades, and international harmonization are enhancing supply-chain resilience. As enterprises, healthcare institutions, and insurers increasingly recognize the economic impact of influenza peaks, vaccines are positioned as the most cost-effective preventive solution, supporting long-term growth.
The industry faces uncertainties due to continuous viral mutation, requiring ongoing strain adaptation and formulation updates that increase R&D and manufacturing pressure. In some countries, limited public awareness or high out-of-pocket vaccination costs lead to fluctuating uptake rates. The reliance on specific upstream materials and specialized manufacturing equipment means that global logistics, regulatory adjustments, or regional policy changes can impact capacity deployment. Annual reports also indicate intensified competition, with novel technology platforms entering rapidly, forcing traditional manufacturers to invest heavily in R&D and production upgrades. Differing cold-chain standards across countries add further complexity to cross-border distribution.
Demand is shifting from “seasonal vaccination” to “routine immunization management,” particularly among high-risk groups such as the elderly, respiratory-disease patients, and healthcare workers. Hospitals, schools, and large enterprises increasingly adopt centralized procurement to mitigate the operational impact during influenza peaks. With rising consumer awareness, quadrivalent vaccines, high-immunogenicity formulations, preservative-free products, and next-generation platforms are seeing faster penetration. Expanded deployment of community clinics, pharmacies, and mobile vaccination points is improving accessibility. Corporate and insurance-driven population-health programs are also steering demand toward higher-quality vaccines.
Key upstream inputs include seed viruses, cell substrates, specialized culture media, adjuvant systems, and sterile-filling consumables, with global suppliers relatively concentrated. Annual reports show that advanced platforms require higher purity, stability, and consistency in antigen and adjuvant materials, increasing the technological intensity and quality sensitivity of the supply chain. As egg-based, cell-based, and recombinant systems evolve in parallel, differences in raw materials have a direct impact on process efficiency and capacity scalability. Requirements for cold-chain packaging, quality-control reagents, and testing consumables are also rising, pushing the upstream ecosystem toward higher standards and broader internationalization.
This report studies the global Vaccine for Influenza production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Vaccine for Influenza and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Vaccine for Influenza that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Vaccine for Influenza total production and demand, 2021-2032, (M Units)
Global Vaccine for Influenza total production value, 2021-2032, (USD Million)
Global Vaccine for Influenza production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (M Units), (based on production site)
Global Vaccine for Influenza consumption by region & country, CAGR, 2021-2032 & (M Units)
U.S. VS China: Vaccine for Influenza domestic production, consumption, key domestic manufacturers and share
Global Vaccine for Influenza production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (M Units)
Global Vaccine for Influenza production by Type, production, value, CAGR, 2021-2032, (USD Million) & (M Units)
Global Vaccine for Influenza production by Application, production, value, CAGR, 2021-2032, (USD Million) & (M Units)
This report profiles key players in the global Vaccine for Influenza market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Vaccine for Influenza market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (M Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Vaccine for Influenza Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Vaccine for Influenza Market, Segmentation by Type:
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Global Vaccine for Influenza Market, Segmentation by Technology:
Chicken Embryo Technology
Cell Culture Technology
Recombinant Technology
Adjuvant Vaccines
Global Vaccine for Influenza Market, Segmentation by Administration:
Injectable
Nasal Spray
Global Vaccine for Influenza Market, Segmentation by Application:
6 Months to 3 Years
> 3 Years
Companies Profiled:
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Key Questions Answered:
1. How big is the global Vaccine for Influenza market?
2. What is the demand of the global Vaccine for Influenza market?
3. What is the year over year growth of the global Vaccine for Influenza market?
4. What is the production and production value of the global Vaccine for Influenza market?
5. Who are the key producers in the global Vaccine for Influenza market?
6. What are the growth factors driving the market demand?
Table of Contents
133 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
